Skip to content
RVBA-NOVOPrivate

Novo Nordisk

DK
Verified credentials
SBTi Validated1.5°C
Decarbonisation trajectory · all scopes
Scope 1 + 2· base 2024 · 101k tCO2eScope 3· base 2024 · 2.2M tCO2e

Headline intensities

Reporting year 2024·Values in USD ($)· normalised from DKK at FY2024 avg rate
Peer cohort: · lower is better
Revenue intensity
Carbon / $m revenue
7.79tCO2e / $m

Carbon per million dollars of revenue. The legacy industry-standard reference (CDP, MSCI). Useful for cross-sector context, but distorted by margin — high-margin firms appear artificially efficient. Read alongside the operational and asset intensities for the full picture.

no peer comparison yet
Operational intensity
Carbon / $m OpEx
tCO2e / $m

OpEx (operating expenditure) is the running cost of the business — staff, services, energy, materials. This shows how carbon-intensive operations are per million dollars of spend. Removes the margin distortion that revenue-based ratios introduce.

no peer comparison yet
Economic intensity
Carbon / $m EVIC
tCO2e / $m

EVIC (Enterprise Value Including Cash) is the firm's total capital footprint — equity + debt + cash + minority interest. The EU's standard intensity measure (SFDR PAI 3) — answers: how much carbon does each million of capital deployed in this business produce?

no peer comparison yet
Asset intensity
Carbon / $m PP&E + leased
13.9tCO2e / $m

PP&E (Property, Plant & Equipment) plus leased real-estate assets is the firm's physical infrastructure on the balance sheet. This shows the carbon intensity of that physical footprint — uses Scope 1+2+3 for consistency with the other headline intensities. Surfaces stranded-asset risk for asset-heavy firms.

no peer comparison yet

Climate action evidence

4 records · 2 sources
Net-zero claim · FY2045 · 1.5°C · sbti
Novo Nordisk A/S commits to reach net-zero greenhouse gas emissions across the value chain by 2045.
Carbon credits retired
No retirement evidence on file (third-party or self-reported).
Renewable electricity
54 %
Self-reported renewable electricity share, FY2024
Sources
  • · berkeley_voluntary_registry
  • · gold_standard
Registry retirements are direct evidence; commitments are forward-looking pledges. EPA snapshot covers FY2019–FY2020.

Strategy & approach

How the firm describes its decarbonisation approach in its own words — alongside the headline numbers above. Self-reported, page-cited.

Approach to renewable energy
100% renewable electricity at all production sites

Novo Nordisk has transitioned to 100% renewable electricity for all production sites since 2020, using Power Purchase Agreements (PPAs), Renewable Electricity Certificates (RECs), and Guarantees of Origin (GOs). Almost all of Novo Nordisk's electricity consumption was procured from renewable sources in 2024. Affiliates reached 99% coverage. Renewable energy accounted for 54% of total energy consumption. More than 1,800 suppliers have committed to transitioning to renewable power. Plans to electrify heat and steam where possible and cover US natural gas consumption with biogas certificates.

Self-reported · FY2024 · p.56
Approach to carbon removals
Carbon removals to neutralise residual emissions beyond 2033

Beyond 2033, Novo Nordisk expects to use carbon removals to neutralise residual CO2e emissions of up to 10% of baseline emissions toward net zero 2045, in line with SBTi requirements and IPCC guidance. Exploring opportunities involving both nature-based and technology-based solutions. Estimates residual emissions after decarbonisation levers to be 150 thousand tonnes CO2e. Does not currently use biodiversity offsets as part of nature roadmap.

Self-reported · FY2024 · p.55
Primary decarbonisation levers
  • Renewable electricity & heat/steam electrification (Scope 1+2)

    Decarbonising own operations through 100% renewable electricity sourcing, energy efficiency programmes (e.g. district cooling ring at Kalundborg expected to save >20,000 MWh/year from 2026), converting steam and heat to renewable energy, electrifying processes, and covering natural gas consumption with biogas certificates. In 2024, energy savings of 13,740 MWh achieved. Target: zero scope 1 and 2 emissions by 2030, with 131 ktCO2e of expected reductions across scope 1+2 by 2030.

  • Reusable injection devices & plastic footprint reduction

    Targeting 30% reduction in plastic per patient by 2033 (baseline 0.35 kg/patient 2024). Transitioning from disposable to reusable devices, developing once-weekly rather than once-daily formulations. Scaling ReMed device take-back scheme to 7 markets with >4 million returned pens. Lower-carbon plastic partnership using e-methanol begins production in 2025.

  • Lower-carbon materials & feedstock substitution

    Switching to low-carbon materials and feedstock across production network including device materials, drug manufacturing inputs, and lower-carbon construction materials. Industrial partnership to purchase e-methanol to produce lower-carbon alternative to one of Novo Nordisk's top two plastic types, with production starting 2025. Explore use of low-impact glucose alternatives in production processes.

Dependent decarbonisation levers
  • Supplier renewable energy transition (Scope 3 cat 1 & 2)

    Working with suppliers to convert tier 1 suppliers to renewable energy. More than 1,800 suppliers have committed to transition to renewable power. Categories 1 (purchased goods) and 2 (capital goods) account for ~80% of scope 3 emissions. Also converting to lower-carbon raw materials and feedstock for device and drug manufacturing, lower-carbon construction materials, and process optimisations to lower material use.

  • Distribution decarbonisation: SAF, SMF and low-carbon road freight

    Lowering distribution emissions through: (1) air freight reduction by converting upstream air freight to sea, plus Sustainable Aviation Fuel (SAF) via long-term off-take agreements; (2) sea freight using Sustainable Marine Fuel (SMF) in upstream distribution; (3) low-carbon road freight solutions both upstream and downstream. Targeting scope 3 categories 4 and 9 to 2033.

Targets

Near-term

3 targets
ScopeBaseTargetReductionAlignmentProgressStatus
Scope 1 + 2Absolute20242030−1%1.5°C
0.0% reductionof −1% target · 0% there
On track
Scope 1 + 2 + 3Absolute20242030In corporate strategyabsolute-value target
Scope 3Absolute20242033−33%
0.0% reductionof −33% target · 0% there
On track

Long-term

2 targets
ScopeBaseTargetReductionAlignmentProgressStatus
Scope 1 + 2Absolute20242045−1%1.5°C
0.0% reductionof −1% target · 0% there
On track
Scope 3Absolute20242045−90%
0.0% reductionof −90% target · 0% there
On track

Net zero

2 targets
ScopeBaseTargetReductionAlignmentProgressStatus
Scope 1 + 2 + 3202420451.5°Cabsolute-value target
Scope 1 + 2 + 32045In corporate strategyabsolute-value target

Progress · absolute tCO2e

Scope 1 + 2 trajectory vs target
Scope 1 + 2 · 1% by 2030 · 1.5°C
ActualLinear1.5°C
Scope 3 trajectory vs target
Scope 3 · 33% by 2033
ActualLinear1.5°C

Latest news· last 5 of 16

full news log →
  • 30% plastic footprint reduction per patient by 2033

    Set global target to reduce plastic per patient by 30% by 2033 vs 2024 baseline of 0.35 kg/patient. Includes transition to reusable devices and circular product design.

    2024
  • Nature roadmap: halt nature loss by 2033, nature-positive by 2045

    Formalised nature roadmap to halt loss of nature in value chain by 2033, and become nature positive by 2045. Includes water withdrawal savings, deforestation-free supply chain ambitions, biodiversity restoration.

    2024
  • Restated scope 3 methodology (cats 1, 2, 4, 6)

    Updated scope 3 methodology for purchased goods, capital goods, upstream transport and business travel. Cat 1 restated from 2,067 to 1,018 ktCO2e; Cat 2 from 1,315 to 303 ktCO2e in 2023. Previously overstated due to spend-based factor uncertainty. Total 2023 scope 3 restated from 1,836 to 1,743 ktCO2e.

    2024
  • Lost-time accident frequency calculation harmonised to international standard

    Changed from 1,600 to 2,000 working hours per FTE per year for accident rate calculation, in line with international standard. Comparatives restated.

    2024
  • First Sustainability Statement under CSRD with double materiality assessment

    2024 is first Sustainability statement prepared under EU CSRD requirements, including double materiality assessment identifying patient protection, climate change, resource use and circular economy, and own workforce as essential topics.

    2024

Latest reporting year· 6 earlier years on Data-by-year tab

all years + ratios →

2026

reporting year
Financials
Revenue
OpEx
FTE
Market cap (FY-end)
Climate
Scope 1
Scope 2 (market)
Scope 2 (location)
Scope 3 total

Source documents· FY2025

all documents →
sustainability report2025
via manual upload · 4.7 MB
extractedOPEN PDF ↗